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Abstract
 .In the adult cerebral cortex, GABA transporters GATs are expressed by both neurons and astrocytes. GAT-1 immunoreactivity is
found in axon terminals of GABAergic neurons and astrocytes, while GAT-3 immunolabeling occurs only in the latter. The present study
was designed to determine whether the expression of GAT-1 and GAT-3 in the adult rat cerebrum changes after needle lesion and
colchicine infusion. Following a needle puncture or a saline injection, immunolabeling for GAT-1 and GAT-3 was slightly increased in an
area around the needle track. Not only was the neuropil labeling for both GATs increased, but also a few neuronal somata were found to
be immunoreactive for GAT-1. Colchicine injections induced a striking increase in immunolabeling for both GATs in the neuropil in an
area adjacent to the needle path and surrounding it. A homologous region of the contralateral hemisphere also showed a moderate increase
of immunoreactivity in the neuropil for both GATs. Furthermore, this contralateral site showed many neuronal somata immunolabeled for
 .GAT-1. These changes were mainly detected during the first 5 days following intracortical lesions. These results indicate that 1 the
upregulation of GAT-1 and GAT-3 in cortical interneurons and astrocytes is caused by both mechanical and chemical factors associated
 .with the injections; 2 increased GAT-1 and GAT-3 expression contralateral to the site of colchicine injection is mediated by
 .transcellular signaling across the corpus callosum; and 3 the lesion-induced GAT expression may play a protective role by helping to
balance excitatory and inhibitory neuronal activities. q 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
 .GABA transporters GATs are recently identified
translemmal proteins in the brain and peripheral tissue
w x4,9,17,32 . They are found in neurons and glial cells in the
nervous system, and functionally have been shown to clear
GABA from the synaptic cleft and extracellular space
w x23,25,26,51 , though they may also be involved in the
secretion of GABA from neurons in a Ca2q-independent,
w xnonvesicular manner in certain circumstances 2,3,31 .
Thus, it is suggested that GATs play an important role in
determining the magnitude and duration of GABA’s neuro-
transmission as well as other activities. To date, four
GATs have been cloned and they are classified as GAT-1,
GAT-2, GAT-3 and GAT-4 according to their differential
amino acid sequences and pharmacological properties
w x4,9,17,32,35 . For example, GAT-1 displays the phar-
macological features typical of a ‘neuronal transporter’ in
) Corresponding author. Fax: q1-949-824-8549; E-mail:
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that its GABA uptake is strongly inhibited by cis-3-
 .aminocyclohexane carboxylic acid ACHC but not by
b-alanine. On the other hand, GAT-2 and GAT-3 are
considered to be ‘glial transporters’ because GABA uptake
via these two GATs is inhibited by b-alanine but not
ACHC. GABA uptake by GAT-4 is inhibited by neither
w xagent 4,9,25,32 .
The cellular and subcellular localization of GATs in the
brain and several sensory organs has been recently studied,
and it appears that GAT-1 and GAT-3 are the major GATs
win the nervous system 5,9,11,21–24,36–39,42,43,45,
x46,51,53,54 . In the adult mammalian cerebral cortex,
GAT-1 mRNA is expressed in the cell bodies of GABAer-
gic interneurons and astrocytes as determined by in situ
w xhybridization 36,42,43 , whereas its protein as shown in
immunocytochemical preparations is mainly found in axon
w xterminals of these neurons and astrocytic processes 36,45 ,
though sparse immunoreaction products are detectable on
the Golgi complex of some interneurons and in the somata
w xof astrocytes at the electron microscopic level 45 . Unlike
GAT-1, GAT-3 is only found in glial elements, i.e., the
0006-8993r99r$ - see front matter q 1999 Elsevier Science B.V. All rights reserved.
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 .  .Fig. 1. Light micrographs showing the immunoreactivity for GAT-1 in homologous areas of the contralateral A–C and ipsilateral D–F neocortex and
hippocampal formation from a rat that survived 2 days after an intracerebral saline injection. The immunolabeling in the contralateral side shows the
 .normal distribution pattern of this GABA transporter in the adult rat cerebral cortex, with the immunoreactivity exclusively localized to neuropil. A the
 .laminar pattern in the neocortex. B is an enlargement of a cortical area in layer III to show that immunonegative pyramidal cell bodies and their axon
 .  .initial segments are contacted by basket and chandelier cell terminals arrows . C shows the normal pattern of GAT-1 immunoreactivity in the neuropil of
 .the hippocampal formation. Following the injection, the cortical areas near the needle track indicated with stars in D and white asterisks in F show a
 .  .  .slight increase of immunoreactivity over the neuropil, and a few lightly stained cell bodies arrowheads in both the neocortex E and hippocampus F .
 .  .  .E is an enlargement of the boxed region in D to show that the labeled somata arrowheads are small, round, and have features of cortical interneurons.
 .CA1 and CA3: CA regions of the hippocampus; s.p.: stratum pyramidale; DG: dentate gyrus; GL: granule cell layer. Scale bars200 mm for A, C, D ,
 .  .100 mm for E, F and 75 mm for B .
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w xastrocytic somata and processes 37,45 . It is important to
note that GAT-1 immunoreactivity is transiently expressed
in the somata and dendrites of interneurons in the neocor-
tex and hippocampus of infant and young rats, aged 5–30
w xdays 53 .
While the distribution of GATs in the normal brain has
been extensively studied, little is known about how the
w xexpression of GATs is regulated 13,15,20,41 . We have
recently shown an increase in immunoreactivity for GAT-1
and GAT-3 in the superior colliculus following deaf-
ferentation from a distant lesion of the optic nerve, sugges-
tive of an upregulation of these GATs following terminal
w xdegeneration 54 . In the present study, we analyzed
whether the immunoreactivity for GAT-1 and GAT-3 in
the cerebral cortex changes following colchicine infusion,
based upon several considerations. First, since colchicine
w xis commonly used to block axonal transport 47 , we were
interested in determining whether it enhances GAT-1 im-
munolabeling in the somata of mature cortical interneu-
rons. Second, colchicine is somewhat neurotoxic and has
been used to create chemical lesions in certain brain
w xregions 19,34 . Thus, we wanted to determine whether
colchicine neurotoxicity alters the immunoreactivity of
GAT-1 and GAT-3 in cortical neurons and glial cells.
Sterile saline was used as the vehicle for colchicine and
the first control for this experiment examined the possible
effect of this vehicle. In addition, as needle penetration can
also cause tissue damage, a second control was used to
verify if and how the mechanical lesion associated with the
needle puncture contributed to cortical expression of GATs.
Unilateral injections were made to the cerebral cortex,
using the contralateral hemisphere as an intrinsic control
for the injected cortex. A preliminary report of this study
w xwas presented elsewhere 48 .
2. Materials and methods
2.1. Animals and surgery
Experiments were performed on male and female adult
 .albino rats Sprague–Dawley weighing 250–350 g. The
animals were anesthetized with sodium pentobarbital 50
.mgrkg, i.p. and placed on a stereotaxic frame. A hole
 .  .Fig. 2. GAT-3 immunoreactivity in homologous areas of the contralateral A and ipsilateral B neocortex and hippocampus from a rat that survived for 2
 .  .days after an intracerebral saline injection stars . A represents a normal distribution pattern of this GAT in the adult rat cerebral cortex with
 .immunolabeling occurring exclusively in the neuropil. B shows a slight increase of immunoreactivity in the neuropil of the neocortical and hippocampal
 .area surrounding the needle track white arrows . IV: layer IV; WM: white matter. Other abbreviations see Fig. 1. Scale bars200 mm.
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was drilled on the left side of the skull at 4.5 mm lateral
and 4.5–5.5 mm posterior to the bregma. A microliter
 .syringe a705, Hamilton, NV that was empty, or loaded
with 7 ml sterile saline, or with 7 mg colchicine Sigma,
.St. Louis diluted in 7 ml saline, was positioned above the
predrilled hole and then advanced into the cerebrum 4.0
w xmm 40 . For colchicine injections, the solution was in-
fused at a constant rate for 3 min and the needle remained
in position for another 5 min before it was withdrawn. The
skin incision was sutured and cleaned. After recovery, the
operated animals were returned to the vivarium, and were
 .  .  .allowed to survive for 1 ns3 , 2 ns3 , 5 ns3 , 10
 .  .ns2 , or 15 ns2 days before perfusion.
2.2. Tissue preparation
Operated animals were deeply re-anesthetized at the
above-indicated time points with sodium pentobarbital and
perfused transcardially with 0.02 M phosphate buffered
 .saline PBS, pH 7.4 followed by 4% paraformaldehyde
 .and 0.2% glutaraldehyde in phosphate buffer pH 7.4 . The
brains were then removed and postfixed in the perfusion
solution for 4–8 h at 48C, and transferred to cold PBS for
several hours to a few days. Brain blocks were prepared to
contain the posterior cerebrum and diencephalon. For ori-
entation purposes, a portion of the ventrolateral cortex
contralateral to the lesion side was removed. The brain
blocks were then sectioned coronally at 40 mm with a
vibratome, and the sections that included the injection site
were collected in tissue-culture wells in cold PBS. They
were further processed for immunocytochemistry and Nissl
staining with cresyl violet.
2.3. Immunocytochemistry
Free-floating sections were stained for GAT-1 and
GAT-3, respectively, using the standard avidin–biotin
 .complex ABC method. At first, endogenous peroxidase
activity was bleached with a 20-min rinse in 0.05% H O2 2
in PBS. Non-specific background staining was lowered
 .with a 2-h incubation in 5% normal horse serum NHS at
room temperature. The sections were further incubated in a
PBS solution containing 5% NHS, 0.3% Triton X-100 and
 .rabbit anti-GAT-1 or GAT-3 1:5000 at 48C for 24 h and
with agitation. After several rinses with PBS, the tissue
was reacted in 1% anti-mouserrabbit IgG with 5% NHS
for 1 h at room temperature, followed by 1% ABC solution
for another hour. The bound antibodies were visualized
with 0.05% DAB and 0.005% H O . Three 10-min rinses2 2
with PBS were used between all incubations.
The primary antibodies were kindly provided by Dr.
w xN.C. Brecha 36,37 and their specificity was verified in
previous studies. Other immunoreactive reagents were pur-
chased from Vector Laboratories. In the present experi-
ments, processing the sections with the primary antibodies
omitted, or replaced by normal horse serum, yielded no
specific immunolabeling.
3. Results
3.1. Injection site and o˝er˝iew of immunolabeling
Pilot experiments were performed to determine the
appropriate volume of vehicle and the amount of colchicine
to be used. Briefly, 5–10 ml of vehicle were found to be
enough to carry the needed amount of colchicine. The
response of the cortex that was injected with this amount
of saline was almost identical to that in the cortex punc-
tured with an empty needle, which in both cases appeared
as a regional and slight increase in immunostaining for
GAT-1 and GAT-3. Injections of 3–7 mg colchicine in-
duced a much greater increase in immunoreactivity in a
larger area than that caused by the needle puncture alone
or with saline injections. In all of these three conditions,
cell loss was only observed within the needle track. Higher
doses of colchicine often resulted in structural distortion
and cell loss in a larger area within and outside the needle
track. As a result, 7 ml vehicle and 7 mg colchicine were
chosen to be used for most animals in our experiments.
The pattern of immunoreactivity in the cerebral cortex
was basically similar for the three short time points 1, 2
.and 5 days postoperation examined in the present study.
We will first describe the pattern of immunolabeling ob-
served in the rats with 2-day survival time. Observations
from the rats survived for 10 and 15 days will be described
at the end of this section.
3.2. Immunoreacti˝ity in the unaffected cortex: normal
distribution pattern
The normal distribution pattern of immunoreactivity for
GAT-1 and GAT-3 in the adult rat cerebral cortex includ-
ing the hippocampal formation has been described in detail
by ourselves and other investigators in previous studies
w x36,37,42,43,45,53 . In the present study, cortical regions
with a normal pattern of immunolabeling were observed in
most cortical areas from rats receiving a puncture lesion or
saline injection. In both cases, the unaffected regions
included the entire contralateral hemisphere and most parts
 .  .Fig. 3. Low magnification light microphotographs showing an altered pattern of immunoreactivity for GAT-1 A and GAT-3 B in both hemispheres
following an unilateral intracortical colchicine injection, 2 days postoperation. The needle track in the ipsilateral hemisphere is indicated with arrows. The
cortical regions with changes in immunoreactivity are bordered by arrowheads. Note the remarkable upregulation of GAT-1 and GAT-3 within and outside
the needle track in the ipsilateral side, and a noticeable increase in a contralateral neocortical region that is symmetric to the affected area on the injected
side. Scale bars1 mm.
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of the ipsilateral cortex except for a zone surrounding the
needle path. In the rats injected with colchicine, the unaf-
fected cortical regions were smaller than those in other
animals, and were medial and ventral to the affected areas
 .see below in both the ipsilateral and contralateral hemi-
spheres.
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For GAT-1, a normal pattern of immunostaining is
shown in Fig. 1A–C, which was obtained from the con-
tralateral cortex of a rat with a saline injection at this same
level. In the neocortex, GAT-1 immunoreactivity was pre-
sent in the neuropil of all six layers, with little immunola-
beling in the white matter. Unlabeled cell bodies were
outlined by immunolabeled puncta in layers II–VI, and
 .were most distinct in the supragranular layers Fig. 1B .
Axonal plexuses surrounding the somata and initial seg-
ments, respectively, of neocortical pyramidal neurons were
 .  .Fig. 4. Higher power views of GAT-1 immunoreactivity in the ipsilateral A–C and contralateral D–F hemispheres 2 days postinjection of colchicine.
 .  .  .A, B, D, E illustrate the transitional areas of increased GAT-1 expression from the affected areas to the medial A, D and ventrolateral B, E unaffected
regions. The general staining intensity is much greater in the affected area of the ipsilateral side than the contralateral side indicated by small arrows in D,
.  .E . The upregulated immunostaining is confined to the neuropil in the affected neocortical and hippocampal areas in the ipsilateral side C , whereas that in
 .  .the contralateral side involves both neuropil and cell bodies in the neocortex F . The CA1 region small white arrows deep to the affected neocortex
 .shows a slight increase of neuropil immunolabeling as compared to other hippocampal regions, but no cell bodies are found E . IV: layer IV. Scale
 .  .bars500 mm for A, B, D, E and 100 mm for C, F .
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found to be GAT-1 immunoreactive in layers IIrIII Fig.
.1B . In the hippocampal formation, the cell bodies of
pyramidal and granule cells were unlabeled, whereas axon
terminals on them and their axon initial segments were
 .immunoreactive for GAT-1 Fig. 1C . GAT-3 immuno-
reactivity in the unaffected cortex was diffusely distributed
in the neuropil in both neocortical and hippocampal areas
 .Fig. 2A .
 .  .Fig. 5. Higher magnification light microphotographs showing GAT-3 immunoreactivity in the affected cortex of ipsilateral A–C and contralateral D–F
hemispheres 2 days after colchicine injection. Note that the increase of immunolabeling is much greater in the ipsilateral side, and that the elevated staining
is exclusively localized to the neuropil on both sides. Deep to the affected neocortex on the ipsilateral side, some small and flat cell bodies with long, thin
 .processes arrows in C are recognizable in the white matter. They represent immunoreactive astrocytes. VIa and VIb: sublamina of layer VI. Scale
 .  .bars200 mm for A, B and 75 mm for B, D .
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3.3. Immunoreacti˝ity in the ipsilateral cortex of control
rats
Both the needle puncture and saline-injected control rats
showed similar changes in immunoreactivity for GAT-1
and GAT-3 in the injected hemisphere. A cortical area
ranging from 100 mm to 500 mm in diameter surrounding
the needle track showed a slight increase in immuno-
staining for both GATs. The degree of the upregulation
 .was generally greater for GAT-1 Fig. 1D–F than GAT-3
 .  .  .Fig. 6. GAT-1 immunoreactivity in the cerebral cortex of a saline-injected A and a colchicine-injected B, C rats 10 days postlesion. A shows that
 .following a saline injection, the upregulation of GAT-1 is only present in the injection site at the corticohippocampal border arrow . With colchicine
 .  .application, the upregulation of GAT-1 remains in the neuropil of a small area arrows surrounding the needle track B , while the corresponding cortical
 .  .  .region in the contralateral hemisphere demonstrates a normal distribution pattern C . Scale bars1.5 mm for A , 300 mm for B, C .
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 .Fig. 2B . Both GAT-1 and GAT-3 showed increased
immunostaining of the neuropil. However, for GAT-1 but
not GAT-3, a few immunoreactive cell bodies were de-
tected within the affected region of the neocortex and
 .hippocampus Fig. 1D,E, Fig. 2B . In the neocortex, GAT-1
immunoreactive neuronal somata were found in all layers
 .except for layer I and the white matter Fig. 1D . They
 .were round, small to medium size 10–15 mm , and lacked
 .identifiable dendritic or axonal processes Fig. 1E . In the
hippocampus, GAT-1 immunoreactive cell bodies were
often observed in stratum pyramidale of CA1, and some of
 .them had immunolabeled dendrites Fig. 1F .
3.4. Immunoreacti˝ity in the ipsilateral cortex of
colchicine-injected rats
The neocortical and hippocampal regions injected with
colchicine displayed a striking increase in the immuno-
 .reactivity for GAT-1 and GAT-3 Fig. 3 . The affected
area was much larger and the amount of expression was
much greater than that in the region around the injected
cortex of the control rats. Thus, the affected region in
colchicine-injected rats was as much as 1r4 to 1r3 of the
cortical area of the entire ipsilateral hemisphere Fig.
.3A,B . The strongest immunolabeling was present at the
needle track and its vicinity, and the intensity of immuno-
reactivity reduced gradually from this central zone toward
the periphery.
At higher magnification, the cellular distribution of this
intense immunolabeling was confined to the neuropil for
 .  .both GAT-1 Fig. 4A–C and GAT-3 Fig. 5A–C . Thus,
no neuronal somata were observed in the injection site and
adjacent areas. The immunonegative cell bodies of pyrami-
dal cells were distinctly outlined by strong neuropil im-
munolabeling for GAT-1 and less so for GAT-3. However,
the size and laminar distribution pattern of these somal
profiles were basically the same as those in the unaffected
cortex, though the increase of neuropil immunoreactivity
resulted in an elevated contrast in the affected region Fig.
.4C, Fig. 5C . In the underlying white matter, some GAT-1
and GAT-3 immunolabeled profiles had long, slender pro-
cesses that resembled the morphological features of astro-
 .cytes Fig. 5C .
3.5. Immunoreacti˝ity in the contralateral cortex of
colchicine-injected rats
In contrast to both the needle puncture and saline-in-
jected controls, rats with colchicine injections had a ho-
mologous region of the contralateral hemisphere that
showed an increased expression of GAT-1 and GAT-3.
This contralateral region was spatially symmetric to the
region with intense GAT expression in the ipsilateral
 .cortex Fig. 3 . The general staining intensity in this
homologous zone was higher than that in the other por-
tions of this hemisphere, but was much lighter than the
regions around the injection site.
At higher magnification, it was found that the GAT-1
immunoreactive changes in the homologous area of the
contralateral side involved both neuronal somata and neu-
 .ropil Fig. 4D–F . Thus, GAT-1 immunolabeled cell bod-
ies were distributed across the cortex, but peaked in layers
 .III and IV parietal cortex at the injection level . The
immunoreaction products were concentrated in the cyto-
plasm and the nucleus of the cell body. The processes of
these cells were mostly unlabeled. If present, they were
very short and probably the proximal dendrites. In contrast
to GAT-1, the increased immunolabeling for GAT-3 in the
homologous zone of the contralateral hemisphere was
 .solely associated with neuropil Fig. 5D–F .
The change in immunostaining in the hippocampal for-
mation of the contralateral hemisphere was less than that
of the neocortex. For GAT-1, a slight increase of neuropil
immunostaining was detectable in the CA1 region deep to
the cortical area that showed alterations in GAT expression
 .Fig. 4E , but no immunoreactive cell bodies were ob-
served. For GAT-3, no immunoreactive changes were de-
 .tectable over the hippocampal formation Fig. 3B .
3.6. Immunoreacti˝ity at later sur˝i˝al time points
At 10 days, the increased immunoreactivity in the nee-
dle puncture or saline-injected controls became very local-
ized to the injection site at the white matter in the ipsilat-
 .eral hemisphere Fig. 6A . For the colchicine-injected rats,
the immunostaining in the neuropil of the contralateral
hemisphere became equivalent to that found in the unaf-
fected regions, and the GAT-1 immunoreactive cell bodies
 .became undetectable Fig. 6C . However, in the injected
side a small cortical area close to the needle track still
 .expressed increased immunostaining for GAT-1 Fig. 6B,C
 .and GAT-3 not shown in the neuropil as compared to
other regions at this stage. By 15 days, it returned to
 .baseline level not shown .
4. Discussion
The present study revealed that the immunoreactivity
for two GABA transporters, GAT-1 and GAT-3, is upregu-
lated in the adult rat cerebral cortex following colchicine
infusion. The increased expression appears not only in the
injected cortical region, but also in its homologous area in
the contralateral hemisphere. Needle punctures and saline
infusions also cause a certain amount of upregulation for
both GATs but it is limited to the area surrounding the
injection site, suggesting that the mechanical lesion associ-
ated with needle penetration is causing a local alteration of
GAT expression. For GAT-1, the elevated expression is
found to be associated with both glia and neurons, and is
most prominent for colchicine-injected rats. The possible
mechanisms and biological significance for the postlesion
upregulation of glial and neuronal GATs observed in the
present study in the adult cerebral cortex are discussed
below.
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4.1. GAT upregulation in astrocytes as a response to
neural injury
The first important finding of the present study is a
localized alteration of GAT-1 and GAT-3 immunoreactiv-
ity in neocortical and hippocampal regions associated with
the mechanical lesion made by needle penetration. A care-
ful histological examination showed that neuronal damage
was limited to the needle track, because the cortical thick-
ness as well as the size, morphology and distribution
pattern of the neurons in the surrounding cortex remained
virtually normal in immunocytochemical and Nissl not
.shown preparations. However, the cortical area that dis-
played an increase of GAT immunolabeling extended be-
yond the needle track and was not limited to only the site
with cell loss caused by the injection needle. Furthermore,
this change in immunostaining was reversible with time.
Thus, the lesion-induced upregulation of GAT-1 and GAT-
3 immunoreactivity observed in the present study may be
triggered by other factors than neuronal death. For exam-
ple, the mechanical lesion caused by needle penetration
w xmay damage neuronal processes 6,12,18,30,33 , resulting
in degenerating axons and activated astrocytes in the area
displaying increased GAT expression. In fact, early studies
had shown that following a needle 2.4 mm external
.diameter lesion in the brain, the astrocytes within a zone
up to 1200 mm from the wound edge were activated and
w xunderwent proliferation 6 . The mitotic activity of the
focal astrocytes was increased between 1–6 days after the
w xneedle lesion 6 . These activated astrocytes became
phagocytes that could remove cell debris, including degen-
w xerating axon terminals 1 . It is possible that these activated
astrocytes are involved in the upregulation of GAT-1 and
GAT-3 in the neuropil of the cortex around the needle
track.
Pertinent to this hypothesis are data from our recent
study that showed increased immunolabeling for GAT-1
and GAT-3 in the rat superior colliculus after optic nerve
w xtransection 54 . This change in GAT expression was
limited to the retinal-recipient layers of the superior col-
liculus and was temporally associated with axon terminal
degeneration following retinal ganglion cell axotomy.
Electron microscopic data indicated that the increased
immunolabeling was found in hypertrophied astrocytes
that were frequently associated with degenerating ganglion
w xcell axons 54 .
Why do colchicine injections induce a much greater
upregulation of GAT-1 and GAT-3 expression in the neu-
ropil than needle punctures or saline injections? First, it
may be that colchicine is stressful to cortical neurons, and
thus induces a more severe neuronal damage and a stronger
glial response than needle puncture does. In fact, cell death
occurs in certain vulnerable neuronal populations, such as
dentate granule cells, following a similar dose of colchicine
w xinjection into the cortex 19,34 . Another possibility is that
colchicine can promote cell division, especially of astro-
w xcytes 6,10 . For example, an intracerebral colchicine infu-
sion increases astrocytic proliferation by 2-fold more than
w xthat caused by needle lesion alone 6 . Thus, the upregula-
tion of GAT expression in the neuropil of the colchicine-
injected cortex is probably enhanced due to astrocytic
proliferation. In fact, immature astrocytes express concen-
trated GAT-1 and GAT-3 in the developing rat cerebral
w x w xcortex 53 and cerebellar cortex own unpublished data .
4.2. Differential regulation of GAT-1 expression in neu-
ronal somata
A novel finding in the present study is that colchicine
infusions caused an increased expression of GAT-1 and
GAT-3 in a homologous region of the contralateral hemi-
sphere. It is important to note that this region showed light
microscopically detectable levels of GAT-1 immuno-
reactivity within the somata of many cortical neurons. Our
results indicated that the laminar pattern, size and somal
shape of these somata resembled the features of neocorti-
w xcal GABAergic interneurons 44,55 . This finding is con-
sistent with the fact that GAT-1 mRNA occurs in
w xGABAergic neurons in the mature cerebrum 36,42,43 .
Neuropil immunolabeling is also enhanced in this selective
contralateral cortical area. As GAT-3 is only contained in
w xastrocytes 37,45 , it is obvious that glial cells in this
region also contribute to the increased neuropil immuno-
staining for GATs, including GAT-1.
The upregulation of GAT-1 and GAT-3 in interneurons
and glial cells in the contralateral hemisphere cannot be
explained by a direct effect of colchicine applied to the
other hemisphere because of the regional selectivity of the
immunoreactive change. Colchicine’s effect on blocking
w xaxonal transport 10,47 cannot explain a glial upregulation
of GATs and an occurrence of GAT-1 only in the cell
bodies of interneurons, because only a few GABAergic
neurons in the adult rat have callosal projections and they
w xare mainly localized to the supragranular layers 16,27 . In
the present study, GAT-1 immunoreactive somata are nu-
merous and distributed throughout the cortical depth.
The increased neuropil immunolabeling in the contralat-
eral side could be a response of the astrocytes in the
vicinity of the callosally projecting axons undergoing ret-
rograde degeneration caused by the injections. On the
other hand, the ‘reactive’ upregulation of GAT-1 in the
neocortical interneurons contralateral to colchicine injec-
tions is likely related to principal neurons in the ipsilateral
hemisphere or those in the contralateral side that project
across the corpus callosum. These neocortical pyramidal
cells are probably activated by these injections, and then
send a signal to GABAergic interneurons, perhaps astro-
w xcytes as well 13 , to induce the alteration of GAT expres-
sion in these latter cells, which is mediated by activation of
glutamate receptors andror the cAMP signal pathway
w x13,15,20,41 . The reason why there is no upregulation of
GATs in GABAergic somata of the contralateral hip-
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pocampal formation could be because hippocampal pyra-
midal cells have a limited point-to-point commissural pro-
w xjection 8,29 .
A similar explanation can be drawn for the expression
of GAT-1 in the neuronal somata of the cerebral cortex
with a needle puncture or saline injection because these
treatments enhance neuronal activity around the needle
path. This notion is supported by the finding of Fos
expression in local neuronal and non-neuronal cells follow-
w xing needle puncture 12 . One result of the present study
that puzzles us the most involves the lack of GAT-1
immunolabeling in interneurons in the colchicine-injected
hemisphere. It is unlikely that GABAergic interneurons in
this region are dying after colchicine infusion because
previous studies used colchicine to label these neurons for
w xGAD 47 . A possible explanation for the absence of
GAT-1 upregulation in GABAergic neurons around the
colchicine-injected cortex may be, again, because this
chemical is somewhat toxic to local neurons. As a result,
the GAT-1 regulatoryrsynthetic system in these interneu-
rons may be somewhat distorted by this neurotoxicity.
4.3. Functional considerations for altered GAT expression
GABA is the major inhibitory neurotransmitter in the
w xnormal adult brain 28 . However, a body of evidence
indicates that it exerts an excitatory effect during develop-
w xment and following neuronal trauma 7,50,52 . GABA’s
action can be regulated by its high affinity transporters,
which take up GABA from the synaptic cleft and extracel-
lular spaces into presynaptic axon terminals and astrocytes,
so that inhibitory synaptic transmission is terminated in a
timely manner and GABA can be recycled into presynaptic
w xterminals 23,26 . In the present study, the upregulation of
GAT-1 and GAT-3 is present mainly in the neuropil in the
neocortical and hippocampal areas around the needle track.
This appearance suggests an enhanced GABA uptake into
astrocytes in the cortical regions with a direct lesion. If
GABA acts as an excitatory substance in the lesioned
cortex, an increased GABA uptake into glial cells would
provide a significant neuroprotective effect for the cortical
neurons.
On the other hand, the upregulation of GAT-1 in the
 .somata of cortical interneurons in the ipsilateral puncture
 .and contralateral colchicine infusion cortex may be to
strengthen the GABA uptake ability for GABAergic neu-
rons. The biological significance of this mechanism is
perhaps to enhance synaptic and non-synaptic GABA re-
w xlease 2,3,31,41,49,56 . As a result, cortical inhibitory
activity is elevated to antagonize neuronal overexcitation
caused either by the stimulation from the needle puncture,
or by transneuronal signaling from the transcallosally pro-
jecting pyramidal cells that are activated after colchicine
injections. Furthermore, since excitation of cortical pyra-
midal neurons appears to be an inductive factor for GAT-1
w xexpression 20,41 , it is possible that a persistent over-
activation or excitation of these cerebral principal neurons
may somehow deplete GAT-1 or interfere with GAT-1
production in the interneurons. This suggestion may ex-
plain why there is a reduction of GABA transporters in
w xhuman temporal lobe epilepsy 14 .
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